Shots:

• The approval is based on P-III IMpower130 study assessing Tecentriq + CT vs CT as monothx. in 681 chemotherapy-naïve patients with stage IV metastatic non-sq NSCLC with no EGFR or ALK genomic tumor aberrations
• The P-III IMpower130 study results: OS (18.6 vs 13.9 mos.); PFS (7.2 vs 6.5 mos.); safety profile is consistent with the profile; no new safety signals were observed
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor and is approved in multiple countries including the US and EU as both monothx. and combination therapy for NSCLC and SCLC- types of m-UC and in PD-L1+ m-triple-negative BC

Click here to­ read full press release/ article 

 Ref: GlobeNewswire | Image: Roche